NetworkNewsBreaks Archive - Page 2206 of 2242

FridayJan 06, 2017 1:36 pm

NetworkNewsBreaks – eMagin Corp. (NYSE: EMAN) Establishes Foundation for Strong 2017

eMagin (NYSE: EMAN) wrapped up a firm fourth quarter that demonstrated the company’s momentum heading into 2017. After launching two products in the final months of 2016, eMagin earlier this week said it will exhibit its products at CES 2017, an annual global consumer electronics and consumer technology tradeshow held this month in Las Vegas. By appointment, eMagin will showcase its highest brightness, direct patterned micro-displays designed for the virtual reality (VR) and augmented reality (AR) markets. The company’s award-winning BlazeSpark smartphone attachment and the BlazeTorch goggles will also be on display. “I am pleased to report we achieved what…

ThursdayJan 05, 2017 2:36 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 5, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CSEI 281.25% – News: Contracted to supply its PwrCor™ engine for clean energy project ETRM 93.30% – News: vBloc Neurometabolic Therapy available at MedStar Health, Roper St. Francis LEON 53.85% – News: Acquires Connecticut-based health care company, Sinol USA PIRS 23.14% – News: Forms collaboration with Servier, an independent international pharmaceutical company PAYD 22.91%– News: Signs merger agreement with emergeIT, Inc. to create new global ecommerce and shipping platform FCSC 23.46% – News: FDA…

ThursdayJan 05, 2017 1:56 pm

NetworkNewsBreaks – Heron Therapeutics, Inc. (NASDAQ: HRTX) – Financials Outweigh Positive HTX-011 Data

Shares of Heron Therapeutics (NASDAQ: HRTX) tumbled from yesterday’s rally after its Q4 Sustol sales results and FY2017 guidance overshadowed separately reported data from phase 2 studies of HTX-011 in patients undergoing bunionectomy (Study 208) and abdominoplasty (Study 203). In a filing, Heron reported Q4 sales of Sustol at $1.1 million and full-year sales of $15 million-$25 million, short of analyst estimates for $2.1 million and $48.8 million, respectively. Regarding the studies: Heron said the results of Study 208 demonstrate statistically significant synergy between the local anesthetic bupivacaine and the anti-inflammatory meloxicam in HTX-011, an extended-release combination product for the…

ThursdayJan 05, 2017 1:45 pm

NetworkNewsBreaks – Cytori (NASDAQ: CYTX) Continues to Advance Cytori Cell Therapy Clinical Trial

Cytori Therapeutics (NASDAQ: CYTX) continues to move forward with its Cytori Cell Therapy™ program, and in mid-December enrolled and treated more than half of the 45 patients in its ADRESU trial in Japan to study the efficacy and safety of Cytori Cell Therapy™ in men with stress urinary incontinence after prostatic intervention for prostate cancer or benign prostatic hypertrophy. Cytori Cell Therapy™ is being developed as a therapy to be delivered in a single treatment, designed to avoid the need for frequent re-treatment. The company reports that the therapy has thus far been well-tolerated and that it expects full enrollment…

ThursdayJan 05, 2017 1:43 pm

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Optimistic as U.S. Housing Hits Record High of $29.6T

Investor confidence in the real estate industry was strong in 2016, evidenced by Zillow research (http://nnw.fm/Qyi23) that shows the value of U.S. housing stock increased to a record $29.6 trillion for the year, up nearly 6% over 2015. Though rising interest rates are likely to yield an unfavorable impact for homebuyers in 2017, eXp World Holdings (OTCQB: EXPI) remains optimistic about its own performance amid the changes. “Most recently, RISMedia (http://nnw.fm/l7zcS) published a study highlighting the fact that more real estate executives are confident about their own local economies than about the world economy. Yet many real estate executives are…

ThursdayJan 05, 2017 10:45 am

NetworkNewsBreaks – How Caladrius Biosciences, Inc. (NASDAQ: CLBS) is Tackling Type 1 Diabetes Mellitus

Autoimmune diseases cost the U.S. more than $100 million annually. Immune tolerance happens, among other things, from the suppression of self-reactive T effector cells and auto-antigen presenting cells by T-regulatory (Treg) cells. A deficit of T-regulatory cells can lead to serious allergic and autoimmune diseases, such as Type 1 diabetes mellitus (T1DM). Caladrius Biosciences (NASDAQ: CLBS) uses T Regulatory Cell Technology to increase autologous T-regulatory cells and function, representing the potential for "true disease modification." The company is developing a therapy based on this technology (CLBS03) for the treatment of T1DM. After announcing positive results for a phase 1 study…

WednesdayJan 04, 2017 2:28 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 4, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: INVE 16.86% – News: Hirsch FICAM solution wins two categories in GSN Awards APVO 11.22% – News: Resumes manufacturing of IXINITY; forecasts new supply in Q2 CATB 10.67% – News: Positive pre-clinical research on CAT-1004 program published in JCI Insight FHCO 8.15% – News: Receives outstanding payment of $2.8M from Brazilian Ministry of Health EFOI 7.46%– News: LED lighting products are first in the United States to be UL-verified with less than 1% flicker…

WednesdayJan 04, 2017 12:28 pm

NetworkNewsBreaks – Concordia International Corp.’s (NASDAQ: CXRX) Shares Buoyed by Agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL)

Concordia International (NASDAQ: CXRX) is trading nearly 4% higher a day after the pharmaceutical company announced its three-year, co-promotion agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) to expand sales of Donnatal®, Concordia's product used in the treatment of irritable bowel syndrome. Per the agreement, RedHill will aim to increase the promotion of Donnatal® among U.S. doctors who treat irritable bowel syndrome. Additionally, RedHill will incur the sales and marketing costs while Concordia will provide materials and samples. Marketing efforts are anticipated to begin during the current quarter. "This agreement is a cost-effective approach to promoting Donnatal® in a manner consistent…

WednesdayJan 04, 2017 12:25 pm

NetworkNewsBreaks – Finjan Holdings, Inc. (NASDAQ: FNJN) Shares Continue Rally on Licensing Agreement, Record Revenues of $18M

Shares of cybersecurity provider Finjan Holdings (NASDAQ: FNJN) are up 9%, continuing a rally on yesterday’s news that the company’s Finjan, Inc. subsidiary is closing a Confidential Patent License Agreement with F5 Networks, Inc. The company also reported record revenues stemming from initiatives to lower costs and maximize efficiencies. "The F5 license agreement is meaningful as it is the first under our enhanced licensing program initiated to streamline efforts, reduce costs and improve efficiencies. As a result of our enforcement efforts we closed a record year at Finjan with more than $18 million in revenue, an almost four-fold increase over…

WednesdayJan 04, 2017 12:22 pm

NetworkNewsBreaks – Inventergy Global, Inc. (NASDAQ: INVT) Kicks-off Patent Licensing Campaign for GTX Corp (GTXO) Technology

IP licensing and innovation company Inventergy Global (NASDAQ: INVT) this morning said its subsidiary, Inventergy Innovations, LLC, has launched a patent licensing campaign for GTX Corp (OTC: GTXO) for its wireless location-based services IP assets based on two-way GPS tracking. As a follow-up to a definitive agreement announced in June 2016, the licensing campaign will provide substantial discounts for early adoption, multi-year commitments or higher volumes of products to companies interested in the Comm. Protocol family. "In our Inventergy Innovations model we obtain exclusive rights to license or sell a partner's patents, technology or in some cases their entire company. We use…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks